AR133154A2 - Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable - Google Patents
Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estableInfo
- Publication number
- AR133154A2 AR133154A2 ARP240101721A ARP240101721A AR133154A2 AR 133154 A2 AR133154 A2 AR 133154A2 AR P240101721 A ARP240101721 A AR P240101721A AR P240101721 A ARP240101721 A AR P240101721A AR 133154 A2 AR133154 A2 AR 133154A2
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- crystals
- lyophilized composition
- formula
- aqueous solution
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Abstract
Los objetos de la presente invención consisten en proporcionar un proceso para producir cristales del compuesto (1) con facilidad en una escala industrial y una composición liofilizada estable de compuesto (1). Se halló que sometiendo una solución acuosa que contiene el compuesto (1) y una sal inorgánica tal como cloruro de sodio a liofilización da como resultado una composición liofilizada con buena estabilidad de almacenamiento, en donde el compuesto (1) es cristalino y también que los cristales del compuesto (1) se pueden obtener de dicha solución acuosa sin liofilización. Reivindicación 1: Un proceso para producir cristales de un compuesto representado por la fórmula (1) caracterizado porque comprende la cristalización del compuesto en una solución acuosa que contiene el compuesto y una sal inorgánica. Reivindicación 7: Un proceso para producir una composición liofilizada caracterizado porque comprende un compuesto representado por la fórmula (1) que comprende la cristalización del compuesto por el proceso de acuerdo con la reivindicación 1. Reivindicación 8: Un proceso para producir una composición liofilizada caracterizado porque comprende un compuesto representado por la fórmula (1) que comprende la cristalización del compuesto sometiendo una solución acuosa que contiene el compuesto y una sal inorgánica a liofilización. Reivindicación 13: Una composición liofilizada, caracterizada porque comprende cristales de un compuesto representado por la fórmula (1) y una sal inorgánica.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014246425 | 2014-12-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR133154A2 true AR133154A2 (es) | 2025-09-03 |
Family
ID=56091802
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103970A AR102915A1 (es) | 2014-12-05 | 2015-12-04 | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable |
| ARP240101721A AR133154A2 (es) | 2014-12-05 | 2024-07-02 | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150103970A AR102915A1 (es) | 2014-12-05 | 2015-12-04 | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10294224B2 (es) |
| EP (1) | EP3228620B1 (es) |
| JP (1) | JP6779787B2 (es) |
| KR (1) | KR102555657B1 (es) |
| CN (1) | CN107001366B (es) |
| AR (2) | AR102915A1 (es) |
| AU (1) | AU2015355970B2 (es) |
| BR (1) | BR112017010445B8 (es) |
| CA (1) | CA2969192C (es) |
| ES (1) | ES2821826T3 (es) |
| IL (1) | IL252691B (es) |
| MX (1) | MX2017007191A (es) |
| MY (1) | MY190283A (es) |
| RU (1) | RU2732129C2 (es) |
| SG (1) | SG11201704576SA (es) |
| TW (1) | TWI691499B (es) |
| WO (1) | WO2016088863A1 (es) |
| ZA (1) | ZA201704063B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ701959A (en) | 2012-05-30 | 2016-07-29 | Meiji Seika Pharma Co Ltd | Novel β-lactamase inhibitor and method for producing same |
| EP3067355B1 (en) | 2013-10-08 | 2020-12-16 | Meiji Seika Pharma Co., Ltd. | Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative |
| SG11201704576SA (en) * | 2014-12-05 | 2017-07-28 | Meiji Seika Pharma Co Ltd | Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation |
| JP7179058B2 (ja) * | 2017-09-27 | 2022-11-28 | Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 | ジアザビシクロオクタン誘導体の剤形およびその生産プロセス |
| EP3687993A1 (en) | 2017-09-27 | 2020-08-05 | Meiji Seika Pharma Co., Ltd. | Pharmaceutical forms of diazabicyclooctane derivatives and manufacturing method thereof |
| KR20200091395A (ko) | 2017-09-27 | 2020-07-30 | 페도라 파마슈티칼스 인코포레이티드 | 디아자비시클로옥탄 유도체의 결정형 및 그의 제조 방법 |
| JP6375463B1 (ja) * | 2018-02-28 | 2018-08-15 | 日本曹達株式会社 | ビス（フルオロスルホニル）アミドアルカリ金属塩粉末の製造方法 |
| CN110314163A (zh) * | 2018-03-30 | 2019-10-11 | 杭州森泽医药科技有限公司 | 一种拉氧头孢钠药物组合物及应用 |
| JP7638693B2 (ja) * | 2020-12-15 | 2025-03-04 | 大阪瓦斯株式会社 | ヒドロキシアルカン酸結晶の製造方法及びヒドロキシアルカン酸の結晶多形体 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6019759B2 (ja) | 1977-11-24 | 1985-05-17 | イ−ライ・リリ−・アンド・カンパニ− | 非経口投予用１１１１５１５２１３９１９９東京都中央区京橋２丁目３番１３号 |
| GB1589317A (en) * | 1977-11-24 | 1981-05-13 | Lilly Co Eli | Freeze drying cephalothin sodium |
| JPS6019759A (ja) | 1983-07-15 | 1985-01-31 | Nippon Soda Co Ltd | ホルムアミドオキシム誘導体その製造方法及び農園芸用殺菌剤 |
| JPS60255723A (ja) | 1984-05-31 | 1985-12-17 | Ono Pharmaceut Co Ltd | メシル酸ガベキサートの結晶性凍結乾燥製剤及びその製造方法 |
| JPH07117533B2 (ja) | 1985-08-28 | 1995-12-18 | 株式会社生体科学研究所 | トランスフエリンおよびその用途 |
| PL157979B1 (pl) | 1989-02-14 | 1992-07-31 | Sprezyna z dwoma stanami równowagi trwalej PL PL | |
| US20030220521A1 (en) | 1989-07-27 | 2003-11-27 | G.D. Searle & Co. | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension |
| TW264475B (es) | 1991-09-20 | 1995-12-01 | Takeda Pharm Industry Co Ltd | |
| JP2843444B2 (ja) * | 1994-05-02 | 1999-01-06 | 塩野義製薬株式会社 | ピロリジルチオカルバペネム誘導体の結晶，該結晶を含む凍結乾燥製剤，およびその製造方法 |
| ATE223916T1 (de) * | 1994-05-02 | 2002-09-15 | Shionogi & Co | Kristalline pyrrolidylthiocarbapenem derivate, lyophilisierste präparationen dieser kristalle und verfahren zu deren herstellung |
| DE19531874C1 (de) | 1995-08-30 | 1996-10-02 | Daimler Benz Ag | Seitenwandbaugruppe für eine Kraftfahrzeugkarosserie |
| TWI233805B (en) * | 1999-07-01 | 2005-06-11 | Fujisawa Pharmaceutical Co | Stabilized pharmaceutical composition in lyophilized form as antifungal agent |
| FR2812635B1 (fr) | 2000-08-01 | 2002-10-11 | Aventis Pharma Sa | Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens |
| FR2825705B1 (fr) | 2001-06-08 | 2005-05-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens |
| FR2835186B1 (fr) | 2002-01-28 | 2006-10-20 | Aventis Pharma Sa | Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases |
| FR2921060B1 (fr) | 2007-09-14 | 2012-06-15 | Novexel | Nouveau procede de preparation d'une piperidine disubsituee et nouveaux intermediaires |
| WO2009091856A2 (en) | 2008-01-18 | 2009-07-23 | Merck & Co., Inc. | Beta-lactamase inhibitors |
| FR2930553B1 (fr) | 2008-04-29 | 2010-05-21 | Novexel | Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases |
| FR2936798B1 (fr) | 2008-10-03 | 2012-09-28 | Novexel | Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens. |
| US20120053350A1 (en) | 2009-04-30 | 2012-03-01 | Ian Mangion | Preparation of alkyl esters of n-protected oxo-azacycloalkylcarboxylic acids |
| FR2951171A1 (fr) | 2009-10-09 | 2011-04-15 | Novexel | Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation |
| US8772490B2 (en) | 2010-12-22 | 2014-07-08 | Meiji Seika Pharma Co., Ltd. | Optically active diazabicyclooctane derivatives and process for preparing the same |
| HUE032491T2 (en) | 2010-12-22 | 2017-09-28 | Meiji Seika Pharma Co Ltd | An optically active diaza-bicyclooctane derivative and a process for its preparation |
| WO2012172368A1 (en) | 2011-06-17 | 2012-12-20 | Astrazeneca Ab | Process for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
| US8822450B2 (en) | 2011-08-27 | 2014-09-02 | Wockhardt Ltd. | 1,6-diazabicyclo [3,2,1] octan-7-one derivatives and their use in the treatment of bacterial infections |
| KR101618424B1 (ko) | 2011-08-30 | 2016-05-04 | 욱크하르트 리미티드 | 1,6-디아자비시클로[3,2,1]옥탄-7-온 유도체 및 세균 감염 치료에서의 그 유도체의 용도 |
| CN103781787B (zh) | 2011-09-13 | 2015-09-23 | 沃克哈特有限公司 | 含氮化合物及其用途 |
| US8796257B2 (en) * | 2011-12-02 | 2014-08-05 | Naeja Pharmaceutical Inc. | Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors |
| US9505761B2 (en) | 2011-12-02 | 2016-11-29 | Fedora Pharmaceuticals Inc. | Bicyclic compounds and their use as antibacterial agents and beta-lactamase inhibitors |
| NZ701959A (en) | 2012-05-30 | 2016-07-29 | Meiji Seika Pharma Co Ltd | Novel β-lactamase inhibitor and method for producing same |
| NZ718009A (en) * | 2013-09-24 | 2018-03-23 | Meiji Seika Pharma Co Ltd | Process for producing diazabicyclooctane derivative and intermediate thereof |
| EP3067355B1 (en) | 2013-10-08 | 2020-12-16 | Meiji Seika Pharma Co., Ltd. | Crystals of diazabicyclooctane derivative and production method for crystals of diazabicyclooctane derivative |
| SG11201704576SA (en) | 2014-12-05 | 2017-07-28 | Meiji Seika Pharma Co Ltd | Method for producing crystals of diazabicyclooctane derivative and stable lyophilized preparation |
-
2015
- 2015-12-04 SG SG11201704576SA patent/SG11201704576SA/en unknown
- 2015-12-04 MY MYPI2017702007A patent/MY190283A/en unknown
- 2015-12-04 US US15/532,281 patent/US10294224B2/en active Active
- 2015-12-04 TW TW104140714A patent/TWI691499B/zh active
- 2015-12-04 KR KR1020177018148A patent/KR102555657B1/ko active Active
- 2015-12-04 MX MX2017007191A patent/MX2017007191A/es active IP Right Grant
- 2015-12-04 CN CN201580065691.6A patent/CN107001366B/zh active Active
- 2015-12-04 AU AU2015355970A patent/AU2015355970B2/en active Active
- 2015-12-04 WO PCT/JP2015/084094 patent/WO2016088863A1/ja not_active Ceased
- 2015-12-04 ES ES15866317T patent/ES2821826T3/es active Active
- 2015-12-04 BR BR112017010445A patent/BR112017010445B8/pt active IP Right Grant
- 2015-12-04 RU RU2017123112A patent/RU2732129C2/ru active
- 2015-12-04 AR ARP150103970A patent/AR102915A1/es not_active Application Discontinuation
- 2015-12-04 EP EP15866317.9A patent/EP3228620B1/en active Active
- 2015-12-04 JP JP2016562689A patent/JP6779787B2/ja active Active
- 2015-12-04 CA CA2969192A patent/CA2969192C/en active Active
-
2017
- 2017-06-05 IL IL252691A patent/IL252691B/en active IP Right Grant
- 2017-06-13 ZA ZA2017/04063A patent/ZA201704063B/en unknown
-
2019
- 2019-03-08 US US16/297,550 patent/US11117895B2/en active Active
-
2024
- 2024-07-02 AR ARP240101721A patent/AR133154A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR133154A2 (es) | Proceso de producción de cristales de derivado de diazabiciclooctano y preparación liofilizada estable | |
| ECSP18094790A (es) | Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas | |
| BR112017027831A2 (pt) | derivados de hidroxiácido, um processo para sua preparação e composições farmacêuticas contendo-os | |
| MX375970B (es) | Compuestos de triazolopirimidina y usos de los mismos. | |
| BR112018075284A2 (pt) | derivados de piperidinila substituída por (hetero)arila, processo para sua preparação e composições farmacêuticas contendo-os | |
| MX2016013689A (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX394386B (es) | Derivado de quinolina muy puro y metodo para su produccion. | |
| MX387483B (es) | Preparación farmacéutica. | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| BR112018006519A2 (pt) | compostos de fórmula, processo para a síntese de compostos, compostos intermediários x, composição, utilização de um composto de fórmula, método para o combate de fungos e semente | |
| MX388969B (es) | Formulas cristalinas de grapiprant. | |
| AR095297A1 (es) | Método para preparar un compuesto de piripiropeno | |
| BR112019009078A2 (pt) | processo para a purificação de pirazolpiridazinas, sal e composição agrícola | |
| MX2017006200A (es) | Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico. | |
| MX2021007536A (es) | Formas de sal y cristalinas de un compuesto organico y composiciones farmaceuticas del mismo. | |
| CY1124838T1 (el) | Αλας παραγωγου κεφαλοσπορινης, κρυσταλλικη, στερεη μορφη αυτου και μεθοδος παραγωγης αυτου | |
| DOP2016000293A (es) | Derivados de diheterociclo enlazado a cicloalquilo | |
| MX2018007415A (es) | Metodos para preparar 5,6-dihidro-6-fenilbenzo[f]isoquinolin-2-ami na sustituida. | |
| EA201791396A1 (ru) | ПРОИЗВОДНЫЕ ИМИДАЗОПИРИДАЗИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PI3Kβ | |
| BR112016018594B8 (pt) | Método para produção do derivado de 2-aciliminopiridina | |
| PE20180453A1 (es) | Derivados de acido (s)-2'-vinil-abscisico | |
| MX379825B (es) | Nuevas formas cristalinas de la sal de monosodio del foramsulfuron. | |
| BR112016024977A2 (pt) | processo para a preparação de polimorfos de imidacloprida | |
| MX2018006534A (es) | Proceso para aislar un derivado de acido (tio) fosforico. | |
| CY1116535T1 (el) | Μεθοδος συνθεσης παραγωγων της 7,8-διμεθοξυ-1,3-διυδρο-2η-3-βενζαζεπιν-2-ονης και εφαρμογη στην συνθεση της ιβαμπραδινης |